Top Markets
#1 Cross Cross +12.78%
#2 Casper Network Casper Network +11.85%
#3 Gama Token Gama Token +9.13%
#4 龙虾 (Lobster) 龙虾 (Lobster) +5.14%
#5 Perle Perle +4.54%
#6 Berachain Berachain +4.52%
#7 Akedo Akedo +4.17%
#8 Humanity Humanity +3.77%
#9 The Innovation Game The Innovation Game +3.74%
#10 Palladium Network Palladium Network +3.67%
Coin of the day
Cross Cross
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Affimed N.V. Affimed N.V.

Affimed N.V.

AFMD
Classifica tra le azioni #36349
Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise,... Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa clinical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.
Prezzo delle azioni
$0.1815
Ultima sincronizzazione: 2026-04-06
Capitalizzazione di mercato
$2.78M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
365.38%
Paese
DE
Scambia Affimed N.V. (AFMD)

Categoria

Healthcare
Ricavi di Affimed N.V. (AFMD)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Affimed N.V., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Affimed N.V. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE